ORIGINAL ARTICLES

JAK2^V617F activating mutation is associated with the myeloproliferative type of chronic myelomonocytic leukaemia

A Pich¹, L Riera², F Sismondi², L Godio¹, L Davico Bonino¹, F Marmont³, P Francia di Celle²

¹ Department of Biomedical Sciences and Human Oncology, Section of Pathology, University of Turin, Turin, Italy
² Center for Experimental Research and Medical Studies (CERMS), Turin, Italy
³ Division of Haematology, San Giovanni Hospital, Turin, Italy

Correspondence to:
^{Correspondence to} Professor Achille Pich, Department of Biomedical Sciences and Human Oncology, Section of Pathology, University of Turin, Via Santena 7, I-10126 Torino, Italy; achille.pich{at}unito.it

Background: Chronic myelomonocytic leukaemia (CMML) is a haematopoietic malignancy with heterogeneous clinical and morphological features. It is classified in the World Health Organization myeloproliferative-myelodysplastic overlap category. JAK2^V617F mutation can be found in a large percentage of patients with myeloproliferative neoplasms.

Aims: To investigate the association between JAK2^V617F mutation and clinical, haematological and bone marrow histological features in CMML and to verify whether the mutation is associated with the myeloproliferative type of the disease.

Methods: 78 consecutive patients with newly diagnosed CMML from 2004 to 2008 were included in the study. JAK2^V617F mutation was assessed using direct sequencing of exon 14 or by allele-specific PCR from total peripheral blood or bone marrow samples.

Results: JAK2^V617F mutation was identified in eight cases (10.2%). All patients with the mutation presented with splenomegaly and had a significantly higher haemoglobin level and neutrophil count than patients without the mutation. All bone marrow biopsies of JAK2^V617F-mutated CMML showed increased erythropoiesis, a marked myeloid and megakaryocytic hyperplasia with occasionally clustered megakaryocytes, and a mild or moderate (grade 1 or 2) fibrosis; six cases showed an increased number of dilated sinusoids and reactive lymphoid nodules.

Conclusions: The results indicate that JAK2^V617F mutation is associated with clinical and morphological features of the myeloproliferative type of CMML. Therefore, JAK2 mutation analysis together with bone marrow morphology could help in a more appropriate classification of the disease.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?